Present status of modified hemoglobin as blood substitutes and oral therapy for end stage renal failure using
1Faculty of Medicine, McGill University, Montreal, Quebec, Canada. artcell@med.mcgill.ca
Abstract:
Artificial cell or bioencapsulation has been developed for use in bioartificial organs, drug delivery, blood substitutes, and other areas. Recent rapid advances in modified hemoglobin blood substitutes have resulted in advance stages of Phase III clinical trials. Another area of use is in oral therapy, using artificial cells microencapsulated with genetically engineered cells for use in end stage renal failure and other conditions.
Related Concept Videos
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Hemodialysis I: Introduction
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
